All In Biotech

Drug Trial Radar · NCT03627468

A Safety Study of BBI-4000 Gel in Patients With Axillary Hyperhidrosis

A Multicenter, Randomized, Open-label, Phase 3 Long-term Safety Study of Topically Applied Sofpironium Bromide (BBI-4000) Gel, 5% and 15% in Subjects With Axillary Hyperhidrosis

Last checked: Nov 20, 2026Latest source record: May 19, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 300 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

300

Actual

Start

Sep 5, 2018

Primary completion

Jan 27, 2020

Study completion Jan 27, 2020

Sponsor

Lead sponsor
Botanix PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Aug 13, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 9 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Hyperhidrosis is a disorder of abnormal excessive sweating. Primary hyperhidrosis (armpits, hands, and feet) affects approximately 4.8% of the US population and is believed to be caused by an overactive cholinergic response of the sweat glands. Current therapies have limited effectiveness, significant side effects, and can be invasive and costly. Sofpironium bromide (BBI-4000) is a novel soft-drug in development for the topical treatment of hyperhidrosis. This Phase 3 study will assess the long-term safety, tolerability, and efficacy of sofpironium bromide gel applied topically to subjects with axillary hyperhidrosis.

Conditions

  • Primary Axillary Hyperhidrosis

Interventions

  • Sofpironium Bromide Gel, 5%Drug

    Sofpironium Bromide Gel, 5%

  • Sofpironium Bromide Gel, 15%Drug

    Sofpironium Bromide Gel, 15%

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The Number of Participants With Treatment Emergent Adverse Events Cumulative to Week 48 by Maximum SeverityTime frame: All safety subjects, reaching week 48 or not
  2. Number of Participants With Post-baseline Local Tolerability Assessments Results by Treatment Group (Population: Safety)Time frame: All Safety Subject, Baseline-Through study completion (48 weeks) or Not

Locations

12 sites in 1 country. Site status is shown where the registry gives one.

  • Coastal Clinical Research, Inc.

    Mobile, Alabama

  • Northwest Arkansas Clinical Trials Center

    Rogers, Arkansas

  • Center for Clinical and Cosmetic Research

    Aventura, Florida

  • Skin Care Research, Inc.

    Boca Raton, Florida

  • Baumann Cosmetic & Research Institute

    Miami, Florida

  • Tory Sullivan MD PA

    North Miami Beach, Florida

  • Research Institute of the Southeast, LLC

    West Palm Beach, Florida

  • Grekin Skin Institute

    Warren, Michigan

  • Minnesota Clinical Study Center

    Fridley, Minnesota

  • Tennessee Clinical Research Center

    Nashville, Tennessee

  • J&S Studies, Inc.

    College Station, Texas

  • Austin Institute for Clinical Research

    Pflugerville, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.